bexarotene indications/contra

Stem definitionDrug idCAS RN
arotinoid derivatives 361 153559-49-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • LGD 1069
  • bexarotene
  • targretin
  • targretyn
  • targrexin
a retinoid X receptor (RXR) selective agonist
  • Molecular weight: 348.49
  • Formula: C24H28O2
  • CLOGP: 8.19
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -6.37
  • ROTB: 3

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
March 29, 2001 EMA
Dec. 29, 1999 FDA VALEANT LUXEMBOURG

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertriglyceridaemia 124.43 45.93 21 265 1683 3383890
Hypothyroidism 92.74 45.93 20 266 5869 3379704
Mycosis fungoides 64.53 45.93 10 276 459 3385114
Blood triglycerides increased 47.11 45.93 11 275 4539 3381034

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01XX25 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
CHEBI has role CHEBI:35610 antineoplastic agent
MeSH PA D016588 Anticarcinogenic Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D020011 Protective Agents
FDA EPC N0000175607 Retinoid
FDA Chemical/Ingredient N0000007700 Retinoids

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Primary cutaneous T-cell lymphoma indication 400122007
Alcoholism contraindication 7200002
Hypothyroidism contraindication 40930008 DOID:1459
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Leukopenia contraindication 84828003 DOID:615
Bilateral cataracts contraindication 95722004
Disorder of biliary tract contraindication 105997008 DOID:9741
Acute pancreatitis contraindication 197456007 DOID:2913
Chronic pancreatitis contraindication 235494005
Disease of liver contraindication 235856003 DOID:409
Diabetic - poor control contraindication 268519009
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.23 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
75MG TARGRETIN VALEANT LUXEMBOURG N021055 Dec. 29, 1999 RX CAPSULE ORAL July 29, 2018 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED 'PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA'

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Retinoic acid receptor RXR-alpha Nuclear hormone receptor AGONIST Kd 7.85 CHEMBL CHEMBL
Retinoic acid receptor RXR-beta Nuclear hormone receptor AGONIST Ki 8.23 CHEMBL CHEMBL
Retinoic acid receptor RXR-gamma Nuclear hormone receptor AGONIST Ki 8.08 CHEMBL CHEMBL
Retinoic acid receptor beta Nuclear hormone receptor Ki 7.30 CHEMBL
Retinoic acid receptor alpha Nuclear hormone receptor Ki 6.74 CHEMBL
Retinoic acid receptor gamma Nuclear hormone receptor Ki 6.89 CHEMBL
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor ANTAGONIST IC50 5.52 IUPHAR
Retinoic acid receptor RXR-gamma Transcription factor Kd 7.54 CHEMBL
Retinoic acid receptor RXR-alpha Transcription factor EC50 7.40 CHEMBL
Retinoic acid receptor RXR-alpha Unclassified EC50 7.40 CHEMBL
Retinoic acid receptor RXR-beta Transcription factor Kd 7.68 CHEMBL

External reference:

scroll-->
IDSource
DB00307 DRUGBANK_ID
2807 IUPHAR_LIGAND_ID
4021197 VUID
N0000148643 NUI
C0765273 UMLSCUI
D03106 KEGG_DRUG
d04507 MMSL
8604 MMSL
233272 RXNORM
116346006 SNOMEDCT_US
387023000 SNOMEDCT_US
4021197 VANDF
N0000006359 NDFRT
N0000148643 NDFRT
008004 NDDF
234760 MMSL
A61RXM4375 UNII
7782 INN_ID
CHEMBL1023 ChEMBL_ID
82146 PUBCHEM_CID
C095105 MESH_SUPPLEMENTAL_RECORD_UI
CHEBI:50859 CHEBI
9RA PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Targretin HUMAN PRESCRIPTION DRUG LABEL 1 0187-5525 GEL 1 g TOPICAL NDA 11 sections
Targretin HUMAN PRESCRIPTION DRUG LABEL 1 0187-5526 CAPSULE, LIQUID FILLED 75 mg ORAL NDA 18 sections
Bexarotene HUMAN PRESCRIPTION DRUG LABEL 1 0378-6955 CAPSULE, LIQUID FILLED 75 mg ORAL ANDA 18 sections
Bexarotene HUMAN PRESCRIPTION DRUG LABEL 1 42292-007 CAPSULE, LIQUID FILLED 75 mg ORAL ANDA 13 sections
bexarotene HUMAN PRESCRIPTION DRUG LABEL 1 68682-002 GEL 1 g TOPICAL NDA authorized generic 11 sections
bexarotene HUMAN PRESCRIPTION DRUG LABEL 1 68682-003 CAPSULE, LIQUID FILLED 75 mg ORAL NDA authorized generic 18 sections